Once-Daily gabapentin 750 MG Oral Tablet — RxCUI 2634751
RxNorm drug concept · Semantic clinical drug
RxCUI 2634751
Semantic clinical drug · SCD
● Current RxNorm concept 15 FDA products
29 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2634751
Official nameOnce-Daily gabapentin 750 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped15
Package NDCs mapped29
Reported Medicaid activity (SDUD)2,634 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Gabapentin: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Gabapentin is mainly used for two things: managing nerve pain that lingers after a shingles infection (called postherpetic neuralgia) in adults, and helping control partial onset s...
- This is a really important question. Taking gabapentin together with opioids like morphine, hydrocodone, or oxycodone significantly raises the risk of serious breathing problems —...
- Can I take gabapentin with my opioid pain medication?
- The most common ones — especially in the first few weeks — are dizziness, drowsiness, and sometimes loss of balance or coordination. Swelling in the feet or hands is also fairly co...
🕸️ Concept Web — How Once-Daily gabapentin 750 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Once-Daily gabapentin 750 MG Oral Tablet
RxCUI 2634751 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Gabapentin
25480IN
-
Gabapentin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Gralise
1087976BN
-
Gralise
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Gabapentin Oral Tablet
378099SCDF -
Gabapentin Oral Product
1156681SCDG -
Gabapentin Pill
1156682SCDG -
Gabapentin Oral Tablet [Gralise]
1115011SBDF -
Gralise Oral Product
1172653SBDG -
Gralise Pill
1172654SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Gabapentin Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Gabapentin 750 MG
2634750SCDC -
Once-Daily gabapentin 750 MG Oral Tablet [Gralise]
2634753SBD -
Gabapentin 750 MG [Gralise]
2634752SBDC
-
Gabapentin 750 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Gabapentin 750 MG
SCDC · 2634750 -
Gabapentin Oral Tablet
SCDF · 378099 -
Gabapentin Oral Product
SCDG · 1156681 -
Gabapentin Pill
SCDG · 1156682
Brand-Name Concepts
-
Once-Daily gabapentin 750 MG Oral Tablet [Gralise]
SBD · 2634753 -
Gabapentin 750 MG [Gralise]
SBDC · 2634752 -
Gabapentin Oral Tablet [Gralise]
SBDF · 1115011 -
Gralise Oral Product
SBDG · 1172653 -
Gralise Pill
SBDG · 1172654 -
Gralise
BN · 1087976
📦 FDA Products & Package NDCs
15 products · 29 package NDCs
29 package NDCs map to RxCUI 2634751 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 52427-0803-90 | 90 TABLET, FILM COATED in 1 BOTTLE (52427-803-90) | Gralise | Almatica Pharma LLC | 2020-10-01 |
| 52427-0804-60 | 60 TABLET, FILM COATED in 1 BOTTLE (52427-804-60) | Gralise | Almatica Pharma LLC | 2023-12-31 |
| 52427-0806-90 | 90 TABLET, FILM COATED in 1 BOTTLE (52427-806-90) | Gralise | Almatica Pharma LLC | 2020-10-01 |
| 52427-0850-60 | 60 TABLET, FILM COATED in 1 BOTTLE (52427-850-60) | Gralise | Almatica Pharma LLC | 2023-12-31 |
| 52427-0890-60 | 60 TABLET, FILM COATED in 1 BOTTLE (52427-890-60) | Gralise | Almatica Pharma LLC | 2023-12-31 |
| 68382-0355-01 | 100 TABLET in 1 BOTTLE (68382-355-01) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0355-14 | 60 TABLET in 1 BOTTLE (68382-355-14) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0356-01 | 100 TABLET in 1 BOTTLE (68382-356-01) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0356-14 | 60 TABLET in 1 BOTTLE (68382-356-14) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0357-01 | 100 TABLET in 1 BOTTLE (68382-357-01) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0357-14 | 60 TABLET in 1 BOTTLE (68382-357-14) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2025-09-18 |
| 68382-0607-05 | 500 TABLET in 1 BOTTLE (68382-607-05) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0607-16 | 90 TABLET in 1 BOTTLE (68382-607-16) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0607-77 | 10 BLISTER PACK in 1 CARTON (68382-607-77) / 10 TABLET in 1... | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0608-05 | 500 TABLET in 1 BOTTLE (68382-608-05) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0608-16 | 90 TABLET in 1 BOTTLE (68382-608-16) | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 68382-0608-77 | 10 BLISTER PACK in 1 CARTON (68382-608-77) / 10 TABLET in 1... | gabapentin | Zydus Pharmaceuticals USA Inc. | 2024-01-25 |
| 70771-1861-02 | 10 TABLET in 1 BLISTER PACK (70771-1861-2) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1861-05 | 500 TABLET in 1 BOTTLE (70771-1861-5) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1861-09 | 90 TABLET in 1 BOTTLE (70771-1861-9) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1862-04 | 10 BLISTER PACK in 1 CARTON (70771-1862-4) / 10 TABLET in 1... | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1862-05 | 500 TABLET in 1 BOTTLE (70771-1862-5) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1862-09 | 90 TABLET in 1 BOTTLE (70771-1862-9) | gabapentin | Zydus Lifesciences Limited | 2024-01-25 |
| 70771-1916-01 | 100 TABLET in 1 BOTTLE (70771-1916-1) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1916-06 | 60 TABLET in 1 BOTTLE (70771-1916-6) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1917-01 | 100 TABLET in 1 BOTTLE (70771-1917-1) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1917-06 | 60 TABLET in 1 BOTTLE (70771-1917-6) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1918-01 | 100 TABLET in 1 BOTTLE (70771-1918-1) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
| 70771-1918-06 | 60 TABLET in 1 BOTTLE (70771-1918-6) | gabapentin | Zydus Lifesciences Limited | 2025-09-18 |
Observed labelers:
Zydus Lifesciences Limited (12) ·
Zydus Pharmaceuticals USA Inc. (12) ·
Almatica Pharma LLC (5)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.